A family office, based in New York City, is looking to invest in therapeutics. The firm is most interested in companies that are IND ready through raising funds for Phase IIb clinical trials. The firm is willing to lead or co-invest, and will invest between $100K-$1.5M, depending on the round and the financial needs of the company. Historically, the firm has focused on investing in US and Israel.

The firm is interested primarily in therapeutics technologies. While agnostic to type of therapeutic, and open to most indications, much of the firm’s previous investments have been in oncology, cardiovascular or CNS related indications. The firm will invest as early as IND-ready companies, but no later than companies raising money for Phase IIb trials.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a large Japanese holding company is seeking to foster innovation across the group by investing in and partnering with strategic startups. In principle, the corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/medical is one of the major focus areas of the holding company, and the corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines.

The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with other business arms within the holding company and can also present opportunities to them as appropriate.

The corporate venture arm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. Through the firm’s strategic relationships, the group can help with Japan market entry and clinical trials, among other areas of needed support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital firm formed in 2017 manages 2 funds, a RMB denominated fund and a parallel USD fund. The firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB $30-150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A California-based firm manages two active funds for both early-stage and growth investments. The firm is interested in investing in early-growth stage healthcare companies; the firm primarily invests in North America, but will consider opportunities worldwide. The firm typically makes Series A investments of ~$5-15M and Series B or later stage investments of ~$20-25 million. The firm is generally a lead investor, but will also enter syndicates with other major investors.

The firm is primarily interested in opportunities across digital health, transformational health IT, and biotech. In digital health, the firm focuses on technologies and services used by consumers or by enterprise/employers; in other categories, the firm has spent time, the firm’s interests include computational tools such as drug discovery tools and back-end solutions that can be used by companies in the clinical trial process during development of new drugs or devices. While the firm typically invests in companies that already have revenue, the firm may consider investing in prerevenue companies provided they have proven product-market fit by other means, such as securing key partnerships.

The firm invests primarily in US-based companies, but considers opportunities in other markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large firm with offices worldwide invests in medical technology companies that are strategically relevant to their business. The firm invests in new technologies via venture investing, incubation, or M&A. The firm invests worldwide.

The firm’s primary focuses within healthcare include diagnostics (particularly point of care diagnostics and molecular diagnostics, patient monitoring, and integrated IoT platforms for health sensors), and digital services (including capacity management, care coordination, technologies that help physicians make diagnoses and other key decisions, and AI technologies in healthcare). The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an external investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare foundation has created a new $150M evergreen fund, and is looking to make 3-4 investments a year. The foundation is interested in therapeutics, diagnostics or screening technology, medical devices, digital health or tech enabled services that advance the fight against cancer. The firm is looking to help these technologies advance to commercialization, investing in IND-ready/clinical stage companies, or post-revenue-generating digital health companies. For earlier stage companies, The firm will invest between $250K-1M, and will invest $3-6M in later stage companies, reserving funds for follow-on investments. The firm is currently looking to co-invest, and will consider global opportunities, but is currently investing mostly in the US

While relatively agnostic to technology within therapeutics, medical devices, diagnostics and digital health, the firm will only invest in companies relevant to the indication of oncology.

The firm is looking for therapeutics companies that are out of Phase I, but will invest in companies as early as IND-ready. For medical device companies, the firm prefers them to be clinical stage. For digital health companies, the firm will consider companies that have >$1M in annual revenues. Currently, the firm is looking to co-invest, but will refer potential portfolio companies to their investment partners for consideration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture firm based in California invests in start-ups developing breakthrough advanced materials and device technologies for specific industry verticals, with a concentration in life sciences and healthcare. The firm is generally a lead investor, and commits $4-8 million per opportunity; the firm also has an active seed fund that can $500K-$1M seed investments.

The firm is invests in life science start-ups developing advanced materials, process, and device technologies. Specific areas of interest include drug discovery platforms, manufacturing platforms, advanced purification and separation techniques, optical devices for diagnostics or manufacturing QC, etc. In diagnostics, the firm is interested in new diagnostic applications of materials science including in sample collection, rapid tests, and biosensors used for real time monitoring. In addition to the aforementioned areas, the firm is broadly interested in ‘blue sky’ applications of materials science in the life sciences. The firm does not invest in clinical development of new therapeutic molecules.

The firm favors companies with platform technologies and partnership-based business models. The firm has deep expertise in manufacturing and productization. Additionally, LPs include large pharma and medical device manufacturing companies; the firm helps portfolio companies develop relationships with these strategics.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.